 AC Immune SA NASDAQ: ACIU and partner Janssen, a unit of Johnson Johnson NYSE: JNJ, have found that an early-stage Alzheimers vaccine spurs induction of antibodies that attack a type of tau, a protein in the brain that contributes to the disease. The interim data for ACI-35.030 come from the high-dose group in Phase 1b2a trial of patients with early Alzheimers. 